PARP Inhibitors Combined with Immune Checkpoint Inhibitors in the Treatment of Gynecological Malignant Tumors
ZHOU Lin
YUAN Lin
WAN Yi-cong
ZHANG Lin
CHENG Wen-jun
JIANG Yi
Abstract：In recent years the progress of targeted therapy and immunotherapy has developed rapidly,such as poly(ADP-ribose)polymerase inhibitor(PARPi)and immune checkpoint inhibitors(ICI)have changed the traditional treatment pattern of gynecologic tumors,but some patients have limited efficacy or develop drug resistance.Preclinical studies have found that PARPi damages DNA repair process,results in increasing tumor mutation burden and tumor-specific antigen neoantigens,modulates the tumor microenvironment,and stimulates the production of tumor infiltrating lymphocytes(TIL)and promotes anti-tumor immune response,which providing a theoretical basis for the combination treatment of PARPi and ICI.Recently,many clinical studies have found that the combination of PARPi and ICI can significantly improve the prognosis of patients with gynecological malignant tumors.
Keywords：Genital neoplasmsfemaleOvarian neoplasmsEndometrial neoplasmsPoly(ADP-ribose)polymerase inhibitorsImmune checkpoint inhibitorsTherapy
Publication Date：2024-04-15
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 206-209,214 )